PubMed COVID-19 Clinical Care

Antibodies play a central role in the immune defense against SARS-CoV-2. Emerging evidence has shown that nonneutralizing antibodies are important for immune defense through Fc-mediated effector functions. Antibody subclass is known to affect

ChAdOx1 nCoV-19 vaccine (so called AZ vaccine), is widely used to prevent the SARS-CoV-2 pandemic and shows powerful effectiveness to deter community transmission. There are common immunogenicity-related side effects such as fever, myalgia, lethargy

No abstract

CONCLUSIONS: The findings of the study suggest that the ways in which the news media discuss epidemics can influence changes in human mobility. It is therefore essential that public health communicators emphasise the basis of scientific evidence to

CONCLUSION: Increased symptoms of depression and anxiety were sustained at the later stage of the pandemic in healthy adolescents. Replication of these findings with a larger sample size would be required to draw firm conclusions.

CONCLUSION: In healthy workers, the two doses of BBIBP-CorV were able to induce humoral immunity; however, 3 months following vaccination, the antibody levels started to decline. The BBIBP-CorV booster injections increase both the quantity and

CONCLUSION: We found no safety concerns for currently administered COVID-19 vaccines during pregnancy. Additional experimental and real-world evidence could enhance vaccination coverage. Robust safety data for non-mRNA-based COVID-19 vaccines are

CONCLUSION: Our study presents the Chinese model of a criminal mandatory treatment system to the international community which has been in operation since the implementation of the new law. Legislatory changes and covid-19 pandemic can have effect on

The COVID-19 outbreak has forced the world to rethink the interconnected health of humans and nature, i.e. One Health (OH). However, the current sector-technology-based solutions have a high cost. We propose a human-oriented One Health (HOH) concept

The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses and the development of new variant-derived vaccines^(1-4). SARS-CoV-2 booster